CLL Society
WHAT’S NEW
Your connection to the most current news, information, and data about Chronic Lymphocytic Leukemia.
We suggest you BOOKMARK this page and visit it often. All content was current as of the date it was published.
In science and in medicine, information is constantly changing. Published content may become out-of-date as new information and data emerge.
Living with CLL
Our CLL Journey
This article is not my CLL journey; this article is our journey. Mine, my wife Michele’s, and my children Jacob (and Sabrina), Rebecca, Emily, and Mathew
CLL Treatment Decision Tool
The goal of the CLL Treatment Decision Tool is to increase your understanding of your chronic lymphocytic leukemia (CLL) and your treatment options.
One Patient’s 10-Year Journey Living With CLL: Hope, Travel, and Community
Judy William’s story is a powerful reminder that a CLL diagnosis doesn’t mean an end to the life you love. It means finding new ways to live it fully.
Dietary and Herbal Supplement Use Among Patients with CLL
Dietary and herbal supplement use is common among patients with CLL with half of patients reporting current or past use.
Genetic Risk Factors and Response to Different CLL Therapies
Patients with CLL and high-risk genetic factors had better outcomes on acalabrutinib-venetoclax combination therapies than on chemoimmunotherapy.
Dr. Ratner offers his memories through the lens of a physician with CLL who specializes in the care of older adults and as a Support Group facilitator.
WHAT'S NEW IN CLL / SLL
Ask the Expert is now Trusted Care Exchange
You may notice a new name on one of CLL Society’s trusted resources.
Our Ask the Expert program is now called Trusted Care Exchange for CLL / SLL. While the name has changed, the program remains the same helpful resource for patients and care partners looking for trustworthy answers to general questions about CLL or SLL.
Through Trusted Care Exchange, you can submit a question and receive guidance from a vetted advanced practitioner. Questions often relate to symptoms, lab results, medications, side effects, nutrition, and other aspects of living with CLL or SLL.
For those who may benefit from more personalized, in-depth support, CLL Society also offers Expert Access. This program connects patients with a physician for a free second opinion through a HIPAA-compliant video platform when a more detailed review of medical history is needed.
No matter where you are in your journey, we’re here to support you with trusted information, compassionate care, and clinical expertise.
ADVOCACY AND POLICY
CLL Society Supports Clinical Trial Modernization
CLL Society Supports Need for Legally Binding Framework for FDA in Rare Diseases
Designing Part B MFP Effectuation to Preserve Access for Patients with Rare Cancers
CLL Society organized a letter to the CMS arguing the agency use its discretion to implement certain IRA provisions so as to support its patients.
CLL Society Endorses Continued Funding for the NIH
CLL Society Supports Need for Legally Binding Framework for FDA in Rare Diseases
UPCOMING EVENTS
Wednesday, August 26, 2026, at 12:30 PM PT / 3:30 PM ET
Join CLL Society for the webinar Understanding the Numbers: A Patient’s Guide to CLL / SLL Testing and Imaging. This webinar will provide a practical overview of the most common tests used in CLL / SLL care and help participants better understand what the results may mean. Discussion will include interpreting blood work and lab results, MRD (measurable residual disease) testing, mutation and genetic testing, imaging scans such as CT, MRI, and PET scans, bone marrow biopsies, and why certain tests are important before starting treatment.
Monday, September 28, 2026, at 10:00 AM PT / 1:00 PM ET
Join CLL Society for the webinar A Guide to CLL / SLL Treatment Selection and Sequencing. This informative webinar features Dr. Jennifer Woyach as she provides an overview of the current CLL treatment landscape and the many options available to patients across their care journey. Drawing on her extensive expertise and clinical experience, she will discuss commonly used treatments for both first-line and relapsed/refractory CLL, including how treatment approaches have evolved over time. The webinar will also explore treatment sequencing—how treatment decisions are made throughout the course of CLL and the factors that help guide therapy selection, including disease characteristics, overall health, prior treatments, side effects, and personal preferences. This webinar and discussion will be slightly advanced, but we invite everyone to join and learn.
On-Demand Replay
If you missed the recent Q&A-style virtual event “Ask Me Anything” with Dr. Joanna Rhodes and patient advocate Jeff Folloder, you can catch the replay and find the transcript here!
If you missed the recent webinar with William A. Werbel, MD, PhD and Brian Koffman, MDCM (retired) MS Ed on Protecting Against Infections When Your Immunity Is Impaired, catch the replay, presentation slides, and transcript here! Watch now!
Treatment Updates
Early Results: Zanubrutinib-Sonrotoclax-Obinutuzumab for CLL
In an early-stage clinical trial, zanubrutinib-sonrotoclax-obinutuzumab was well tolerated and all patients with CLL / SLL responded to treatment.
Recruiting Trial: Sonrotoclax Plus Zanubrutinib for CLL
An ongoing phase 3 study is comparing the efficacy of sonrotoclax plus zanubrutinib with acalabrutinib plus venetoclax in patients with untreated CLL.
Real-World Comparison of Zanubrutinib Versus Acalabrutinib
Real-world data suggests that patients with CLL treated with first-line zanubrutinib have better outcomes than those treated with acalabrutinib.
Equitable Access and Regulatory News
FDA Approves Sonrotoclax for Mantle Cell Lymphoma
On May 13, 2026, the FDA approved sonrotoclax (Beqalzi from BeOne), a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma (MCL).
FDA Approves Combo of Acalabrutinib and Venetoclax in CLL
The FDA has approved acalabrutinib and venetoclax as the first all oral combination for previously untreated CLL patients based on the AMPLIFY trial data.
FDA Okays Pirtobrutinib Post Covalent BTKi Treatment
On Dec. 3, 2025 the FDA gave full approval to pirtobrutinib for use in chronic lymphocytic leukemia (CLL) after treatment with a covalent BTK inhibitor.